Search
Pharmacoda, a tech firm dedicated to AI-powered drug discovery, has declared the successful completion of its Series B funding, totaling $52 million, raised in multiple stages. This round of funding has attracted participation from numerous investment institutions and industry-specific funds, with WinX Capital acting as the sole financial advisor. The capital raised will be primarily allocated to drive technological advancements in the company’s proprietary full-chain AI drug development engine, MAP (Molecule Arts Platform). Specifically, the funds will support the enhancement of its multi-agent collaborative system and clinical data feedback loop, propel the Phase III clinical development of its self-developed oral GLP-1RA small molecule drug, MDR-001, towards commercialization, and expedite the expansion of its pipeline featuring differentiated innovative drugs.
-
C114 Communication Network -
Communication Home
